Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Jen Wieczner
Stay informed with Jen Wieczner’s coverage and analysis for Coins2Day.
Page 44 of 51
Health
Here’s one way Obamacare is backfiring
By
Research Team
MPW
Why Wall Street loves to hate Mylan’s CEO
By
News Correspondent
Finance
This drug-industry deal would be the largest hostile takeover in history
By
Investment Desk
Finance
Meet Europe’s best activist investor
By
Senior Editor
Tech
Apple’s stock is now officially in a bear market
By
News Correspondent
Tech
Indonesia’s ‘Uber of moto-taxis’ is even more hated than Uber
By
Crypto Correspondent
Retail
Walmart CEO Doug McMillon posts $25 million gift on Instagram
By
Blockchain Reporter
MPW
Valeant had the hots for ‘female Viagra,’ Sprout CEO says
By
Industry Analyst
Tech
Here’s what happened inside Google HQ when Alphabet was announced
By
Digital Assets Editor
Finance
Depomed goes hostile against Horizon Pharma’s takeover bid
By
Research Team
International
How much Delta’s lion head trophy ban could cost Africa’s economy
By
Blockchain Reporter
Retail
Apple Watch arrived at Best Buy today
By
Market Analyst
Finance
From Actavis to Allergan: One pharma company’s wild dealmaking journey
By
Stacy Jones
,
Kacy Burdette
, and others
Finance
The real reasons for the pharma merger boom
By
Financial Writer
Finance
These are the best Global 500 stocks to buy
By
Financial Writer